HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    
Now Available: Top 10 Stocks for 2010

These powerful long-term stocks for 2010 have just been announced. Our top picks for 2009 generated a +34.1% return. Don’t miss out. Learn more now.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


DGX: Quest Diagnostics Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

QUEST DIAGNOSTICS INC (NYSE)
DGX 55.68 0.68 (1.24%) Vol.  1,148,325 16:03 ET

Day Low - High 54.99 - 56.11
52wk Low - High 42.36 - 62.83
Avg Volume 1,332,408
Industry MED-OUTP/HM CRE
Market Cap 10.17 B
Div - Yield 0.40 - 0.73
PE (forward) 13.04
PEG Ratio 1.06
Current Year Est. 4.22
EPS Last Year 3.88
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


downgraded 01/27/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 12/21/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
QUEST DIAGNOSTICS INC DGX PREMIUM
AMEDISYS INC AMED PREMIUM
CHEMED CORP CHE PREMIUM
CONTINUCARE CRP CNU PREMIUM
See all MED-OUTP/HM CRE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.33
ABR (Last Week) 2.33
# of Recs in ABR 18
Average Target Price 64.00
Industry Rank by ABR 128 out of 217
Rank in Industry 19 out of 30
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate DGX?
Buy
Sell
Find out what the Zacks Community
thinks of DGX at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR DGX
Zacks Blog: Quest Beats, Guides In-Line
Jan 25, 2010
Zacks Blog: Company News for January 25, 2010
Jan 25, 2010
Zacks Equity Research: Report for DGX
Dec 21, 2009
Zacks Blog: Quest Outperforms, Ups Outlook
Oct 21, 2009
Zacks Blog: Monogram Deal Inches Forward
Jul 21, 2009
Zacks Blog: Bayer Deal Not Enough for Celera
Jun 30, 2009
Zacks Blog: Zacks Industry Rank Analysis Highlights: Stericycle, Quest Diagnostic, Biogen Idec, AmeriSourceBergen, Abbott Labs, Tesoro, AK Steel, Nucor, United States Steel,...
Jun 25, 2009
Zacks Blog: Zacks Analyst Blog Highlights: LabCorp, Monogram Biosciences, Inc., Pfizer, Quest Diagnostics and Myriad Genetics
Jun 24, 2009
More Zacks Commentary
NEWS
SmarTrend research report available on Quest Diagnostics (NYSE:DGX)
Feb 08, 2010
Quest Diagnostics Shares Sharply Lower, Down 1.5% (DGX)
Feb 08, 2010
Quest Diagnostics Reaffirms
Feb 05, 2010
Quest Diagnostics to Speak at the UBS Global Healthcare Services Conference
Feb 05, 2010
Health Discovery Corporation Partners with Major New York City Pancreatic Cancer Center to Develop a New Molecular Diagnostic Test for the Early Detection of Pancreatic Cancer
Feb 05, 2010
Vermillion Pays Health Discovery Corporation Final Patent Infringement Settlement Payment
Feb 03, 2010
BUYINS.NET: (DGX) SqueezeTrigger Price is $56.981. There is $200,120,832.00 That Short Sellers Still Need To Cover
Feb 03, 2010
BUYINS.NET: (DGX) SqueezeTrigger Price is $56.984. There is $199,980,544.00 That Short Sellers Still Need To Cover
Jan 28, 2010
More News
EARNINGS ESTIMATES
  This Quarter
03/2010
Next Quarter
06/2010
This Year
12/2010
Next Year
12/2011
Average Estimate 0.98 1.08 4.22 4.63
Number of Estimates 18 17 19 18
Low Estimates 0.95 1.04 4.10 4.35
High Estimate 1.01 1.11 4.32 4.85
Year Ago EPS 0.89 1.00 3.87 4.22
EPS Growth 9.93% 8.47% 9.00% 9.78%

More Estimates

COMPANY DESCRIPTION
Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Full Company Report
FINANCIALS
EPS TTM 3.88
Sales 7455.2
Net Income 729.1
Price/Earnings 14.18
Price/Book 2.54
Price/Cash Flow 13.28
Price/Sales 1.36


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research